



3 November 2015

ASX ANNOUNCEMENT

Harvard Clinical Research Institute Agreement

Brisbane, Australia - **ImpediMed Limited** (ASX: IPD) a leading provider of technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into an agreement with the prestigious Harvard Clinical Research Institute (HCRI) located in Boston, Massachusetts, to advance research around the use of bioimpedance spectroscopy (BIS) in fluid detection. Initial activities under the Agreement include organising and managing a medical advisory board to assess the use of BIS in chronic heart failure patients.

"We are delighted to be working with such a prestigious institute to identify the potential role for BIS in the management of chronic heart failure," said Richard Carreon, Managing Director and CEO. "We believe our BIS technology could provide a cost effective solution for better management of fluid detection and accumulation in chronic disease management."

- ENDS -

Richard Carreon
Managing Director & CEO

For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer

For personal use only

survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

About Harvard Clinical Research Institute

Harvard Clinical Research Institute's (HCRI) mission is to improve health and quality of life by collaborating with academic and industry sponsors to conduct high-quality clinical research in a professionally nurturing and world-class academic environment. HCRI accomplishes this by collaborating with a diverse network of academic researchers to offer expertise in a broad range of therapeutic areas. Since 1999, HCRI's CEC has provided sponsors with high quality and consistent adjudication of reported endpoints and is built on the foundation of expertise, leadership, quality, and experience. Examples of this include the conception and leadership of numerous Academic Research Consortia (ARC, VARC, and BARC), adjudication and analysis for FDA special panel meetings, and the support of over 100 successful PMA and NDA submissions. HCRI is known to have extensive experience in Cardiovascular devices and drugs, and also has experience in Psychiatry, Heart Failure, Hepatology, and Nephrology. More information is available at <http://www.hcri.harvard.edu/>.

For personal use only